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The nonsteroidal anti-inflammatory drug aspirin and the spice curcumin retard adenoma formation when administered long-term to
Apc
Min/+ mice, a model of human familial adenomatous polyposis coli. Both agents interfere with cyclooxygenase activity. When
aspirin is administered to Apc
Min/+ mice only postweaning, but not before, it is inefficacious, while curcumin given postweaning is
active. Here the hypothesis was tested that dietary aspirin (0.05%) or curcumin (0.2%) prevent or delay adenoma formation in
offsprings when administered to Apc
Min/+ mothers and up to the end of weaning, but not afterwards. Whereas curcumin was without
effect when administered in this way, aspirin reduced numbers of intestinal adenomas by 21%. When aspirin given up to the end of
weaning was combined with curcumin administered from the end of weaning for the rest of the animals’ lifetime, intestinal adenoma
numbers were reduced by 38%. The combination was not superior to intervention postweaning with curcumin alone. These results
show that aspirin exerts chemopreventive activity in the Apc
Min/+ mouse during tumour initiation/early promotion, while curcumin is
efficacious when given at a later stage of carcinogenic progression. Thus, the results suggest that in this mouse model aspirin and
curcumin act during different ‘windows’ of neoplastic development.
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It has been estimated that over half of the Western population
develops benign adenomatous polyps during its lifetime, and that
10% of these tumours proceed to malignant colorectal carcinoma
(Kinzler and Vogelstein, 1996). This realisation has engendered an
intense search for efficacious chemopreventive intervention
strategies using animal models of premalignant and malignant
colorectal cancer. The ‘multiple intestinal neoplasia’ (Apc
Min/+)
mouse model of human familial adenomatous polyposis (Moser
et al, 1990) has been instrumental in the identification of several
potential chemopreventive drug candidates, among them nonster-
oidal anti-inflammatory drugs (NSAIDs), exemplified by sulindac
(Boolbol et al, 1996) and aspirin (Mahmoud et al, 1998), and the
spice curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-
diene-3,5-dione (Mahmoud et al, 2000; Perkins et al, 2002).
Curcumin is the major yellow pigment extracted from turmeric,
the powdered rhizome of the herb Curcuma longa. Interestingly,
the evidence for the chemopreventive efficacy of aspirin in
Apc
Min/+ mice, and similar models involving mutant Apc is
ambiguous. In two studies in Apc
Min/+ mice, aspirin suppressed
malignancy (Barnes and Lee, 1998; Mahmoud et al, 1998), while in
two others in Apc
Min/+ and Apc
1638N/+ mice it failed to show
efficacy (Williamson et al, 1999; Chiu et al, 2000). This discrepancy
is probably related to differences in the aspirin regimen used in
these studies, a notion borne out by the recent finding that
continual exposure of Apc
Min/+ mice to aspirin from the point of
conception onwards suppressed tumorigenesis, while exposure
during adulthood only did not (Sansom et al, 2001). It is not
known whether aspirin retains its efficacy in this model when
given only during embryogenesis and weaning, without being
present in the diet thereafter. Mechanistically curcumin shares
with aspirin the ability to interfere with levels of functional
cyclooxygenase (COX) enzymes. While aspirin inhibits COX
enzyme activity (Vane, 1971), curcumin interferes with the
NFkB-mediated activation of COX-2 transcription (Plummer et al,
1999). An attractive feature of curcumin is the fact that it fails to
elicit detrimental gastrointestinal side effects associated with
traditional NSAIDs, such as aspirin. In the study described here,
we wished to explore whether dietary aspirin and/or curcumin
retard neoplastic development in the Apc
Min/+ mouse when
administered in utero and during weaning, without being present
in the diet thereafter. Aspirin was found to be efficacious when
administered in this way, but curcumin was inactive. Therefore,
the hypothesis was tested that a combination of aspirin in utero
and during weaning followed by curcumin postweaning results in
additive or synergistic adenoma-suppressing activity, as this
regimen might exploit age-related differences in susceptibility of
Apc
Min/+ mice to the cancer-delaying effects of these agents.
MATERIALS AND METHODS
Experiments in mice were conducted as stipulated by the Animals
(Scientific Procedures) Act 1986 Project Licence 80/1250 granted to
Leicester University by the UK Home Office, and the experimental
design was vetted and approved by the Leicester University Ethical
Committee for Animal Experimentation. C57BL/6J male Apc
Min/+
mice and C57Bl/6J female wild-type mice were mated to maintain
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Min/+ breeding colony. Tissue samples were obtained by ear
punch and genotyped for Min/+ status by PCR and HindIII digest
of the product as described previously (Luongo et al, 1994).
Curcumin and aspirin were purchased from Apin Chemicals
(Abingdon, UK) and Sigma (Poole, UK), respectively. The purity of
curcumin was verified by HPLC analysis; this material contained
3% desmethoxycurcumin. Aspirin or curcumin was blended into
RM3 high protein breeders diet (SDS, Witham, UK), using a
mechanical mixer to ensure uniform distribution, which was
confirmed by HPLC analysis. Breeding pairs were established and
fed RM3 maintenance diet or RM3 containing either 0.05% aspirin,
which translates into 75mgkg
1 pd, or 0.2% curcumin, which
translates into 300mgkg
1 pd. After 2 weeks, the females were
removed and maintained on their respective diets, until the
offspring were removed and genotyped at 3 weeks of age. At 30
days, the offspring with the Min/+ phenotype were divided into
three intervention groups of eight to 10 animals (Figure 1): (i) mice
that received RM3 control diet, (ii) mice that received either
aspirin or curcumin in RM3 diet perinatally and during days 1–30,
followed by RM3 diet omitting aspirin/curcumin to the end of the
experiment; (iii) mice that received aspirin perinatally and during
days 1–30, followed by curcumin in RM3 diet from weaning to the
end of the experiment. The early administration regimen will be
referred to in the following as ‘in utero and during weaning’, the
late regime as ‘postweaning’. An experiment, in which mice
received curcumin postweaning to the end of the experiment, has
been performed previously in this laboratory (Perkins et al, 2002)
and was not repeated here to reduce animal usage. At 120 days,
mice were killed by cardiac exsanguination under terminal
halothane anaesthesia. The gastrointestinal tract was removed,
and multiplicity, location and size of adenomas were recorded as
described previously (Perkins et al, 2002). Adenoma numbers
values were subjected to statistical evaluation by ANOVA using
Excel and Minitab software packages (Microsoft Windows, 1997).
Statistical significance (Po0.05) was established by post hoc
Tukey’s pairwise comparison. The haematocrit, the percentage of
blood volume occupied by packed erythrocytes, was determined as
described previously (Strumia et al, 1954) using blood samples
collected and drawn by capillary force into heparinised micro-
haematocrit tubes (75mm, Richardson’s, Leicester, UK).
RESULTS AND DISCUSSION
Administration of aspirin (0.05%) in utero and during weaning in
Apc
Min/+ mice and maintaining mice on aspirin-free diet there-
after, reduced tumour burden in the small intestine by 21%
(Figure 2). This result is consistent with the notion that the
majority of adenomas in Apc
Min/+ mice are fixed already either in
utero or perinatally just after birth (Shoemaker et al, 1995; Ritland
and Gendler, 1999) It suggests, for the first time, that interference
with tumour initiation and/or early promotion in Apc
Min/+ mice
can have a long-term beneficial consequence, even if the
chemopreventive stimulus is discontinued postweaning. A similar
reduction was observed in the colon, however overall colonic
adenoma burden was so low that the difference between exposed
and unexposed mice was not significant (result not shown). The
modest but significant reduction of intestinal adenoma burden by
aspirin is consistent with previous work according to which long-
term dietary administration of aspirin from conception onwards
increased the survival of Apc
Min/+ mice, while exposure during
adulthood only did not (Sansom et al, 2001). The failure of aspirin
to attenuate neoplastic development in Apc
Min/+ mice, when
administered postweaning only, has been demonstrated in at least
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Figure 1 Experimental design for the evaluation of the chemopreventive
efficacy of aspirin (0.05%) or curcumin (0.2%) administered in the diet in
utero and during weaning, or of curcumin from termination of weaning to
the end of the experiment, or of the combination of aspirin in utero and
during weaning followed by curcumin postweaning. RM3 was the control
diet. The study was terminated after 120 days. For details of animals and




























































































































Figure 2 Effect on adenoma burden in the small intestine of Apc
Min/+
mice of aspirin (‘asp’, 0.05% in the diet, open bar) or curcumin (‘curc’, 0.2%
in the diet) administered in utero and during weaning (‘preweaning’, bar
striped diagonally bottom left to top right), or of curcumin administered
postweaning to the end of the lifetime (‘postweaning’, bar striped diagonally
top left to bottom right), or of the combination of aspirin in utero and
during weaning followed by curcumin postweaning (black bar). Adenoma
burden is expressed as percentage of number of adenomas in untreated
mice, the number of mice used per group was eight to 10. The value for
the effect of curcumin postweaning (bar striped diagonally top left to
bottom right) was obtained previously (Perkins et al, 2002) and has been
included for comparison; this experiment was not repeated here to
minimise animal usage. The results originate from three separate
experiments, and number of intestinal adenomas in the control (untreated)
groups were as follows: experiment described by open and black bars:
132712, experiment described by bar diagonally striped bottom left to
top right: 117713, experiment described by bar striped diagonally top left
to bottom right: 115712. The s.d.s of adenoma number values for the
different interventions are 12% of the mean, or smaller. Asterisk indicates
that the number of adenomas is significantly different from that in control
(untreated) animals (Po0.05). For details of animals and treatments and
statistical evaluation, see Materials and Methods.
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set al, 2002). In contrast, there are reports that document
convincingly the ability of two NSAIDs other than aspirin,
piroxicam (Ritland and Gendler, 1999) and celecoxib (Jacoby
et al, 2000b), to decrease the number of established polyps and
to prevent the development of nascent ones, when they
are administered at a late stage during the lifetime of Apc
Min/+
mice.
Detailed analysis of the results obtained for aspirin reveals that
administration in utero and during weaning reduced the number
of middle-sized adenomas, those of 1–3mm diameter, in both the
middle and distal regions of the small intestine (Figure 3). The
decrease in tumour size intimates that aspirin delays adenoma
development, rather then totally suppressing the emergence of a
subset of adenomas. The efficacy of aspirin when it is administered
in utero and during weaning only suggests that in the Apc
Min/+
mouse there is a ‘window of opportunity’ for preventive
intervention using aspirin, and this window occurs in very young
mice. A similar window of susceptibility allowing regulation of
tumour development in Apc
Min/+ mice has been suggested by
results of experiments in which the effect of the carcinogen N-
ethyl-N-nitrososurea on the formation of crypts and adenomas was
studied (Shoemaker et al, 1995).
In contrast to aspirin, dietary curcumin (0.2%) administered
in utero and during weaning only, failed to affect adenoma number
(Figure 2). This finding suggests that high preventive efficacy at
the stage of tumour initiation/early promotion is not a generic
feature of all agents that target COX enzymes. In contrast,
curcumin administered later, that is, from the end of weaning
for the lifetime, reduced intestinal adenoma burden in Apc
Min/+
mice by 39%, compared to untreated mice (Figure 2, reference
Perkins et al, 2002).
These results warrant interpretation in terms of our knowledge
of the pharmacokinetics of aspirin and curcumin. Aspirin is
efficiently absorbed, rapidly distributed and swiftly hydrolysed in
the biophase to salicylate, which in turn is eliminated via the
kidneys and/or undergoes phase II drug metabolism (Needs and
Brooks, 1985). Furthermore, salicylate generated by hydrolysis of
aspirin reaches breast milk readily (Findlay et al, 1981). When
administered to the mother, salicylates are rapidly transferred to
the fetus (Schoenfeld et al, 1992). As aspirin has a short half-life,
only a small amount of unmetabolised drug reaches the fetus,
which is therefore exposed mainly to its metabolite salicylate.
Compared to the adult organism, the fetus has reduced abilities of
salicylate plasma protein binding, biotransformation and drug
elimination. Therefore, fetusses and newborns whose mothers
received aspirin before delivery may have plasma concentrations
of free salicylate up to four times higher than those of their
mothers (Schoenfeld et al, 1992). The finding that aspirin exerted
chemopreventive efficacy when administered in utero and during
weaning is consistent with these pharmacokinetic considerations,
in that efficacy was probably the consequence of efficacious levels
of salicylate in the mother’s milk and the embryonic blood and
tissues. In contrast, the absorption of curcumin is poor and its
systemic availability is extremely low in all species in which it has
thus far been tested (Ireson et al, 2001). Therefore, when curcumin
was administered in utero and during weaning in Apc
Min/+ mice,
levels of drug which reached the maternal blood and milk and the
fetal organism were conceivably insufficient to elicit chemopre-
ventive efficacy.
Sequential administration in Apc
Min/+ mice of firstly aspirin
in utero and during weaning and secondly curcumin given
postweaning for the remainder of the animals’ lifetime decreased
mean tumour burden slightly, but not significantly, more than the
aspirin-only regimen (Figure 2). The extent of adenoma reduction
by the combination was also not superior to intervention with
curcumin alone administered postweaning (Figure 2). Analysis of
tumour distribution (Figure 3) shows that sequential intervention
with aspirin followed by curcumin significantly reduced the
number of small adenomas in the proximal and distal regions
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Figure 3 Effect of dietary aspirin (0.05%) administered in utero and during weaning (bars 1) or of the combination (bars 2) of aspirin, given as above, with
dietary curcumin (0.2%), administered postweaning to the end of the experiment, on multiplicity of small (o1mm diameter, open bars) medium size (1–
3mm, hatched bars) or large (43mm, closed bars) adenomas in the proximal (A), middle (B), distal (C) or colonic (D) sections of the intestine of Apc
Min/+
mice. Results are expressed as mean number of adenomas over or below mean adenoma numbers in control (untreated) Apc
Min/+ mice. Number of mice
per group was eight to 10. Asterisk indicates that the number of adenomas in that segment was significantly different from that in the respective segment in
control animals (Po0.05). For details of animals and treatments and statistical evaluation see, Materials and Methods.
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swhich is comparable to the efficacy characteristics of curcumin
alone (Perkins et al, 2002).
Even though aspirin and curcumin are considered to act
via similar modes of action by decreasing levels of active
COX enzymes, there are clear differences between them
as reflected by the age-related discrepancy in susceptibility
of Apc
Min/+ mice towards drug activity. On the one hand, aspirin
and curcumin seem to exert optimal adenoma-retarding activity
at different stages of the lifetime of Apc
Min/+ mice, aspirin early
and curcumin late; on the other hand, we failed to observe
additivity or synergy when both agents were administered
sequentially. Together these findings are consistent with the
notion that in this mouse model aspirin and curcumin exert their
activities probably on the same cells, but within different
‘developmental windows’.
The administration regimens involving aspirin in utero and
during weaning alone or in combination prior to curcumin had no
detrimental effect on propensity towards gastrointestinal bleeding,
as reflected by the haematocrit (results not shown), nor did they
cause gastric erosion and loss of mucosal integrity, as adjudged by
macroscopic inspection. These side effects are often associated
with long-term administration of NSAIDs.
What is the corollary of these results for cancer chemoprevention
in humans? In utero a d m i n i s t r a t i o no fd r u g si so b v i o u s l yn o ta
feasible intervention strategy in humans. Nevertheless, the proof of
principle study described here allows the conclusion that that there
seem to be different ‘windows of susceptibility’ during preneoplastic
and neoplastic development, in which agents exert their preventive
activities differentially, at least in the Apc
Min+ mouse. Applied to
humans this realisation adds another layer of complexity to the
design optimisation of intervention trials using combinations of
agents. Multiagent chemoprevention strategies in Apc
Min/+ mice
which have been efficacious are combinations of piroxicam with
difluoromethylornithine (Jacoby et al, 2000a), and of sulindac with
the epidermal growth factor receptor kinase inhibitor EKI-569
(Torrance et al, 2000) or with tea polyphenols (Orner et al,2 0 0 2 ) .A
better delineation of the developmental window which permits
optimal efficacy for each agent might help to improve the use of
combination chemoprevention strategies in humans.
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